Author

H. Eng

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 1 Approach:machine learning (classical)· 1 Organism:mouse· 1 Research Focus:protein folding & dynamics· 1 Assay:proteomics· 1 Organism:virus· 1

Frequent Co-Authors

B. Boras· 2 shared L. Aschenbrenner· 2 shared Y. Zhu· 2 shared A. A. Lee· 1 shared A. Balesano· 1 shared A. Behzadi· 1 shared A. D. Mesecar· 1 shared A. Ephron· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

B. Boras

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The co-chaperone DNAJA2 buffers proteasomal degradation of cytosolic proteins with missense mutations

H. A. Baker, J. P. Bernardini, V. Csizmok, A. Madero, S. Kamat, H. Eng, J. Lacoste, F. Yeung, S. Comyn, G. Calabrese, M. Taipale, B. Raught, T. Mayor

The paper identifies cytosolic mutant proteins degraded by the proteasome and shows DNAJA2 stabilizes some mutants while being dispensable for wild-type proteins.

bioRxiv · Feb 15, 2024Cell Biology

Discovery of SARS-CoV-2 papain-like protease (PLpro) inhibitors with efficacy in a murine infection model

M. R. Garnsey, M. C. Robinson, L. T. Nguyen, R. Cardin, J. Tillotson, E. Mashalidis, Y. Aijia, L. Aschenbrenner, A. Balesano, A. Behzadi, B. Boras, J. S. Chang, H. Eng, A. Ephron, T. Foley, , A. A. Lee

This study identifies potent SARS-CoV-2 PLpro inhibitors using machine learning, showing efficacy in a mouse model of COVID-19.

bioRxiv · Jan 26, 2024 · PreprintMicrobiology

Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19

B. Boras, R. M. Jones, B. J. Anson, D. Arenson, L. Aschenbrenner, M. A. Bakowski, N. Beutler, J. Binder, E. Chen, H. Eng, J. Hammond, R. Hoffman, E. P. Kadar, R. Kania, E. Kimoto, , M. E. McGrath

This study identifies PF-00835321 as a potent inhibitor of SARS-CoV-2 3CL protease with in vitro antiviral activity and clinical evaluation potential.

bioRxiv · Sep 12, 2020 · PreprintPharmacology & Toxicology